Factors associated with successful treatment of smoking
DOI:
https://doi.org/10.19230/jonnpr.2016.1.4.1028Keywords:
Cigarette smoking, Cardiovascular risk factors, Concomitant diseases, Smoking cessation success.Abstract
Objectives: To assess the success of smoking cessation treatment, according to sex, comorbidities and treatments used.
Method: Retrospective, descriptive study of the results obtained after analyzing the sample of all patients who attended the “Specialized Smoking Treatment” Unit in the University Hospital of Albacete from the 1st of January 2008 until the 31st of December 2009 and the subsequent posterior year follow-up.
Results: 838 patients sent from Primary Care and Pneumology Service were included. 53.7% were men. The average age of the sample was 46.18 years. The average daily cigarette consumption was over a pack daily with 27.30 cigarettes per day.
Most of the patients had comorbidities; among which was psychiatric comorbidity (37.7%), cardiovascular risk factors (CVRFs); among which the most common factor was dyslipidemia followed by hypertension and diabetes, and respiratory comorbidity (COPD, obstructive sleep apnea, asthma and chronic carriers of Domiciliary Oxygen Therapy). The global success in patients who attended the first consultation was (13.8%), while the success in patients who did not abandon the study without
starting the treatment was 27.6%). With the variable “Respiratory Diseases / Cardiovascular Diseases” (RD/CVD) it was observed that having a respiratory or a cardiovascular disease
does not influence the success of smoking cessation. There are hardly any differences in the success probability according to whether the patient is suffering or not hypertension, diabetes, dyslipidemia,
psychiatric disorder, alcoholism or neoplasias. However statistical difference between success and the possibility of being diagnosed or not with SAHS was observed (p <0.028). Nor were found differences regarding the number of previous attempts to quit before starting the treatment and success. Moreover, the success was calculated according to the number of cigarettes smoked per day, but no statistically significant difference was found for a 95% confidence interval.
Conclusions: In our study, cardiovascular or psychiatric comorbidities have no influence on quitting smoking success.
Downloads
References
González-Enríquez J, Villar-Alvarez F, Banegas-Banegas JR, Rodríguez-Artalejo F, MartínMoreno JM.
Tendencia de la mortalidad atribuible al tabaquismo en España, 1978-1992: 600.000 muertes en 15 años. Med
Clin (Barc) 1997; 109: 577-582.
Taylor WC, Pass TM, Shepard DS, Komaroff AL Cholesterol reduction and life expectancy. A model incorporating
multiple risk factors. Ann Intern Med 1987;106:605-14.10
Becoña-Iglesias E (Coord). Libro blanco sobre el tabaquismo en España. Barcelona: Glosa Ediciones, 1998.
Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tobacco
Control 1994; 3: 242-247.
Villalbí JR. Tabaquismo. En: Navarro C, Cabasés JM, Tormo JM. La salud y el sistema sanitario en España.
Informe SESPAS 1995; Barcelona: SG Editores, 1995; 83-89.
Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolomen H et al. Estimation of contribution of
changes in classic risk factors to trends in cornary-event rates across the WHO MONICA Project populations.
Lancet 2000; 355: 675-687.
Borrás JM, Fernández E, Schiaffino A, Borrell C, La Vecchia C. Pattern of smoking initiation in Catalonia, Spain,
from 1948 to 1992. American Journal of Public Health, 90, 9, pp. 1459-1462.
Villalbí JR, Barniol J, Nebot M, Díez E, Ballestín M. Tendencias en el tabaquismo de los escolares: Barcelona,
-1996. Aten Primaria 1999; 23: 359-362.
Barrueco M,Hernández-Mezquita MA, Torrecilla M. Manual de Prevención y Tratamiento del tabaquismo. 2ª ed.
Majadahonda (Madrid): Ergon; 2003.
A g e n cy for Health Care Po l i cy and Research on Smoking Cessation. The A g e n cy for Health Care Policy
and Research on Smoking Cessation Clinical Practice Guideline. JAMA 1996; 275:1270-1280.
Alonso Gordo JM, Magro Pretejer R, Martínez Pérez JA, Sanz Bonacho N. Tabaco y Atención Primaria. En: Libro
Blanco del tabaquismo en España. C ap. 12. Comité Nacional para la Prevención del Tabaquismo. Barcelona:
Glosa; 1998.
Nebot M, Cabezas C, Oller M. Consejo médico, consejo de enfermería y chicle de nicotina para dejar de fumar
en atención primaria. Med Clin (Barc) 1990; 95: 57-61.
Martín-Cantera C, Cordoba-García R, Jané-Julio C, Nebot-Adell M, Galan-Herrea S, Aliaga M et al. Evaluación a
medio plazo de un programa de ayuda a los fumadores. Med Clin (Barc) 1997; 109: 744-748.
Brotons C, Iglesias M, Martín-Zurro A, Martín-Rabadan M, Gené J. Evaluation of preventive and health promotion
activities in 166 primary care practices in Spain. Fam Pract 1996; 13: 144-151.
Nebot M, Borrell C, Ballestín M, Villalbí JR. Prevalencia y características asociadas al consumo de tabaco en
población general en Barcelona entre 1983 y 1992. Rev Clin Esp 1996; 196: 359-64.
Banegas JR, Díez L, Bañuelos B, González J, Martín-Moreno JM, Córdoba R, et al. La mortalidad atribuible al
consumo de tabaco en España en 2006. Med Clin (Barc) 2010. doi:10.1016/j.medcli.2010.03.039
Gorgojo Jiménez, L.; González Enríquez, J.; Salvador Llivina, T. Evaluación de la eficacia, efectividad y costeefectividad
de los distintos abordajes terapéuticos para dejar de fumar AETS - Instituto de Salud Carlos III 2003.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an
alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for
smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine. replacement therapy for smoking cessation.
Cochrane Database Syst Rev, 2004
Josep M.ª Borràs. La perspectiva del género en el cáncer: una visión relevante y necesaria. Arbor, Vol 191, No
(2015). doi:10.3989/arbor.2015.773n3001
Pardell H, Saltó E, Canela J, Salleras L. Smoking cessation rates after three months treatment with nicotine patch
among health professionals in Catalonia, Spain. Int J Smoking Cessation 1993; 2: 35-37.
Moragues L, Nebot M, Ballestin M, Salto E. Evaluación de una intervención comunitaria (programa ‘quit and win’)
para dejar de fumar. Gac Sanit 1999; 13:456-461.
Becoña E, Vázquez FL, Míguez MC. The smoking cessation program of the University of Santiago de
Compostela 1984-96. En: Smoke-free Europe. Helsinki: Finnish Centre for Health Education, 1996;
Jiménez-Ruiz CA, Solano Reina S, González de Vega JM, Ruiz Pardo M, Flórez Martín S, Ramos Pinedo A. y
cols. Normativa para el tratamiento del tabaquismo. Arch Bronconeumol 1999; 335: 499-506.
Jiménez-Ruiz CA, de Granda Orive JI, Solano Reina S, Carrion F, Romero Palacios P, Barrueco Ferrero M.
Recomendaciones para el tratamiento del tabaquismo. Arch Bronconeumol 2003; 39: 514-523.
Rodríguez Hermosa JL, Calle Rubio M, Álvarez-Sala Walther JL. Módulo 8: Tratamiento I. Unidad 7. Bupropión.
En: Máster en Prevención y Tratamiento del Tabaquismo. Instituto for Lifelong Learning. Universitat de
Barcelona. Edición UB virtual. 2008.
Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KE, Williams KE, Billing CB. The efficacy and
safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized
controlled trial. Curr Med Res Op. 2008; 24:1931-41.
Hays T, Ebbert J. Adverse effects and tolerability of medications for the treatment of tobacco use dependence.
Drugs 2010; 70:2557-72.
UD Department of Health and Human Services. Women and smoking. A report of the Surgeon General.
Rockville: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General,
Jané M, Saltó E, Pardell H, Tresserras R, Guayta R, Taberner JL, et al. Prevalencia del tabaquismo en Cataluña
-1998: una perspectiva de género. Med Clin 2002; 118:81-5.
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley SS. Exploring the impact of
gender and reproductive status on outcomes in randomized clinical trial of naltrexone augmentation of nicotine
patch. Drug Alcohol Depend. 2010; 1:112(1-2):1-8. Epub 2010 Jun 19.
Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, Loh WY. Gender, race, and education
differences in abstinence rates among participants in two randomized smoking cessation trials. Nic Tob Res
; 12(6):647-57.
Russell MA, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Targeting heavy smokers
in general practice: randomised controlled trial of transdermal nicotine patches. Br Med J 1993; 306:1308-12.
Camarelles F, Asensio A, Jiménez Ruiz C, Becerril B, Rodero D, Vidaller O. Efectividad de la intervención grupal
para la deshabituación tabáquica. Ensayo clínico aleatorizado. Med Clin 2002; 119:53-7.
Ramón JM, Bou R, Alkiza ME, Romea S, Oromí J, Saltó E, et al. Proceso de cambio y sexo como predictores del
abandono del consumo de tabaco. Arch Bronconeumol 1999; 35:488-93.
Nebot M, Soler-Vila M, Martín-Cantera C, Birules-Pons M, Oller-Colom M, Sala-Carbonell E, et al. Efectividad del
consejo médico para dejar de fumar: evaluación del impacto al año de la intervención. Rev Clin Esp 1989;
:201-5.
García M, Schiaffino A, Twose J, Borrell C, Saltó E, Peris M, et al. Abandono del consumo de tabaco en una
cohorte de base poblacional. Arch Bronconeumol 2004; 40:348-54.
Caponnetto P, Polosa R, Smoking cessation: tips for improving success rates. Breathe 2008; 5:16-12.
Pascual-Lledó JF, de la Cruz-Amorós E, Bustamante-Navarro R, Buades-Sánchez R, Contreras-Santos C,
Castillo-Aguilar C. Abstinencia de tabaquismo tras 12 meses de seguimiento en una unidad de tabaquismo
integral. Med Clin (Barc). 2006; 126: 601-606.
Bauld L, Judge K, Platt S. Assessing the impact of smoking cessation services on reducing health inequalities in
England: observational study. Tob Control 2007; 16:400-404 doi:10.1136/tc.2007.021626.
Woolacott N, Jones L, Forbes C, Mather L, Sowden A, Song F, et al. NHS Centre for Reviews and Dissemination.
A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement
therapy (NRT) for smoking cessation.The National Institute for Clinical Excellence, ed. York: University of York,
World Bank. Curbing the epidemic: Governments and the Economics of tobacco control. A World Bank
Publication. Washington DC: The World Bank; 1999.
J. Fernández de Bobadilla Osorio1, C. Sánchez-Maestre2, M. Brosa Riestra3, O. Arroyo4, V. Sanz de Burgoa4,
K. Wilson5.Cost effectiveness analysis of varenicline (Champix®) for the treatment of smoking in Spain. An. Med.
Interna (Madrid) v.25 n.7 Madrid jul. 2008
Luján R. Negative results: the unwanted but much-needed side of research.JONNPR.2016;1(3):81-3.
DOI:10.19230/jonnpr.2016.1.3.1009
Cahill K, Stead LF, Lancaster T Nicotine receptor partial agonists for smoking cessation (Review). The Cochrane
Collaboration 2007
Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
